Cost-Effectiveness of a National Opportunistic Screening Program for Atrial Fibrillation in Ireland

被引:22
作者
Moran, Patrick S. [1 ,2 ]
Teljeur, Conor [2 ,3 ]
Harrington, Patricia [2 ]
Smith, Susan M. [4 ]
Smyth, Breda [5 ]
Harbison, Joseph [6 ]
Normand, Charles [7 ]
Ryan, Mairin [2 ,8 ]
机构
[1] Trinity Coll Dublin, Sch Med, Hlth Policy & Management, Foster Pl, Dublin 2, Ireland
[2] Hlth Informat & Qual Author, Hlth Technol Assessment, Dublin, Ireland
[3] Trinity Coll Dublin, Dept Publ Hlth & Primary Care, Dublin, Ireland
[4] Royal Coll Surgeons Ireland, Dept Gen Practice, Dublin, Ireland
[5] Merlin Pk Univ Hosp, Dept Publ Hlth, Hlth Serv Execut, Galway, Ireland
[6] St James Hosp, Trinity Coll Dublin, Hlth Sci Ctr, Dublin, Ireland
[7] Trinity Coll Dublin, Sch Med, Dept Hlth Policy & Management, Dublin, Ireland
[8] Trinity Coll Dublin, Dept Pharmacol & Therapeut, Dublin, Ireland
关键词
atrial fibrillation; pulse palpation; screening; stroke; QUALITY-OF-LIFE; LONG-TERM SURVIVAL; STROKE PREVENTION; ISCHEMIC-STROKE; INTRACEREBRAL HEMORRHAGE; ANTITHROMBOTIC TREATMENT; ORAL ANTICOAGULANTS; GENERAL-POPULATION; SYSTEMIC EMBOLISM; RHYTHM-MANAGEMENT;
D O I
10.1016/j.jval.2016.07.007
中图分类号
F [经济];
学科分类号
02 ;
摘要
Objectives: To evaluate the cost-effectiveness of a national atrial fibrillation screening program in Ireland involving annual opportunistic pulse palpation of all those older than 65 years during general practitioner consultations, with an electrocardiogram being performed if an irregular pulse is detected. Methods: A probabilistic Markov model was used to simulate costs and clinical outcomes in a hypothetical cohort of men and women with and without screening over the course of 25 years, using a societal perspective. Results: Screening was associated with an incremental cost-effectiveness ratio of 23,004/quality-adjusted life-year compared with routine care. Nevertheless, if the relative risk of stroke and systematic embolism in screen-detected patients is more than 12% lower than that in patients with atrial fibrillation identified through routine practice, then screening would not be considered cost-effective at a willingness-to-pay threshold of 45,000/quality-adjusted life-year. An analysis comparing alternative combinations of start age and screening interval found that less frequent screening with a later start age may be more cost-effective than an annual screening from age 65 years. Conclusions: Annual opportunistic screening of men and women aged 65 years and older in primary care in Ireland is likely to be cost-effective using conventional willingness-to-pay thresholds, assuming that those detected through screening have a comparable stroke risk profile as those detected through routine practice. Raising the start age of screening or increasing the screening interval may improve the cost-effectiveness of a prospective screening program.
引用
收藏
页码:985 / 995
页数:11
相关论文
共 50 条
  • [41] Anticoagulation Therapy for Atrial Fibrillation in Patients With Alzheimer's Disease A Cost-Effectiveness Analysis
    Vargas, Estefania Ruiz
    Sposato, Luciano A.
    Lee, Spencer A. W.
    Hachinski, Vladimir
    Cipriano, Lauren E.
    STROKE, 2018, 49 (12) : 2844 - 2850
  • [42] Cost-effectiveness of targeted screening for non-valvular atrial fibrillation in the United Kingdom in older patients using digital approaches
    Patel, Shreeya
    Kongnakorn, Thitima
    Nikolaou, Andreas
    Javaid, Yassir
    Mokgokong, Ruth
    JOURNAL OF MEDICAL ECONOMICS, 2023, 26 (01) : 326 - 334
  • [43] Evaluating the cost-effectiveness of catheter ablation of atrial fibrillation
    Iroegbu, Chukwuemeka Daniel
    Chen, Wangping
    Wu, Xun
    Cheng, Luo
    Zhang, Hao
    Wu, Ming
    Zhao, Yuan
    Liu, Li Ming
    Yang, Jinfu
    CARDIOVASCULAR DIAGNOSIS AND THERAPY, 2020, 10 (05) : 1200 - +
  • [44] Evaluating the Cost-effectiveness of Catheter Ablation of Atrial Fibrillation
    Chang, Andrew Y.
    Kaiser, Daniel
    Ullal, Aditya
    Perino, Alexander C.
    Heidenreich, Paul A.
    Turakhia, Mintu P.
    ARRHYTHMIA & ELECTROPHYSIOLOGY REVIEW, 2014, 3 (03) : 177 - 183
  • [45] Cost-effectiveness in medical and interventional treatment in atrial fibrillation
    Cohen, A.
    Leclercq, C.
    ARCHIVES OF CARDIOVASCULAR DISEASES SUPPLEMENTS, 2016, 8 (02) : 144 - 156
  • [46] Cost-Effectiveness of Bridging Anticoagulation Among Patients with Nonvalvular Atrial Fibrillation
    Pappas, Matthew A.
    Barnes, Geoffrey D.
    Vijan, Sandeep
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2019, 34 (04) : 583 - 590
  • [47] Use of mHealth Devices to Screen for Atrial Fibrillation: Cost-Effectiveness Analysis
    Giebel, Godwin D.
    JMIR MHEALTH AND UHEALTH, 2020, 8 (10):
  • [48] Cost-effectiveness of pharmacogenetic-guided dosing of phenprocoumon in atrial fibrillation
    Verhoef, Talitha I.
    Redekop, William K.
    Veenstra, David L.
    Thariani, Rahber
    Beltman, Peter A.
    van Schie, Rianne M. F.
    de Boer, Anthonius
    Maitland-van der Zee, Anke-Hilse
    PHARMACOGENOMICS, 2013, 14 (08) : 869 - 883
  • [49] Cost-effectiveness of apixaban compared to warfarin in the management of atrial fibrillation in Australia
    Ademi, Zanfina
    Pasupathi, Kumar
    Liew, Danny
    EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2015, 22 (03) : 344 - 353
  • [50] Opportunistic Screening for Subclinical Atrial Fibrillation: It Is Cost-Effective, but Is It Effective?
    Zeitler, Emily P.
    Chew, Derek S.
    Mark, Daniel B.
    CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES, 2023, 16 (11):